Psychedelic ExperiencesNCT06581263
Psychedelic Virtual Reality
An observational study of Psychedelic Experiences and Virtual Reality, run by Yale University at 1 site in United States.
Trial summary
The purpose of this study is to evaluate a novel VRP. Read more about this study
- Who is it for?
- Ages 21 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Psychedelic Experiences, Virtual Reality, Healthy Volunteer
- What is being tested?
- Meta Quest 3
- Type of treatment
- Medical device
- How many people
- 10 participants
- Where
- 1 siteUnited States
- Study dates
- 22 Jul 2025to 22 Mar 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Healthy volunteers
Who may be able to join
- Ability to provide informed consent
- No history or current DSM-V diagnosis
Who cannot join
- Unstable medical conditions
Trial locations and contacts
1 site in 1 country.
United States1 site
Yale University School of Medicine
New Haven, Connecticut, 06510
About this study
Official title: Investigating the Use of Virtual Reality in Psychedelic Research or Clinical Practice
The purpose of this study is to evaluate a novel VRP.
Read the detailed description
The primary objective of this study is to determine whether the subjective experience of a novel VRP (DeepDream) will be comparable to a standard dose of psychedelics. This study also looks to compare the subjective experience of DeepDream VRP to other available VR modalities developed to mimic psychedelic subjective experience along with assessing the incidence of VRP adverse effects.
- Conditions
- Psychedelic Experiences, Virtual Reality, Healthy Volunteer
- Being tested
- Meta Quest 3
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Meta Quest 3Device
Meta Quest 3 is a virtual reality headset device
| Study group | Role | What they receive |
|---|---|---|
| Healthy Volunteer | Not described Receives: Device: Meta Quest 3 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Assess subjective experience of novel VRP (DeepDream) comparable to a standard dose of psychedelics.
Subject experience will be assessed using the Altered States of Consciousness Rating Scale.
Measured: Day 0 through Day 30
Assess subjective experience of novel VRP (DeepDream) comparable to a standard dose of psychedelics.
Subject experience will be assessed using the Mystical Experience Questionnaire.
Measured: Day 0 through Day 30
Assess subjective experience of novel VRP (DeepDream) comparable to a standard dose of psychedelics.
Subject experience will be assessed using the Ego-Dissolution Inventory.
Measured: Day 0 through Day 30
Secondary outcomes (1)
Assess the incidence of VRP adverse effects, principally virtual reality sickness (VRS) and neck and upper back pain.
The number of adverse events will be assessed through qualitative interviews following VRP viewing.
Measured: Day 0 through Day 30
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Sep 2024
- Study start22 Jul 2025
- Primary completion22 Mar 2026
- Study completion22 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Psychedelic ExperiencesStudies of the same condition, open and under way.
- More trials run by Yale UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case crossover
- Time perspective
- Other
- Enrolment
- 10 participants (actual)
Sponsor and investigators
- Lead sponsor
- Yale University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Anahita Bassir Nia, Yale University
- Investigators
- Anahita Bassir Nia, MD, Principal investigator, Yale University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06581263
- Sponsor's protocol ID
- 2000038121
- Status last verified
- Aug 2026
- First submitted
- 27 Aug 2024
- Last updated
- 18 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigating the Use of Virtual Reality in Psychedelic Research or Clinical Practice
- ClinicalTrials.gov ID
- NCT06581263
- Acronym / sponsor ID
- 2000038121
- Conditions
- Psychedelic Experiences, Virtual Reality, Healthy Volunteer
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 10 participants (actual)
- Lead sponsor
- Yale UniversityUniversity, hospital or other
- Study start
- 22 Jul 2025 (actual)
- Primary completion
- 22 Mar 2026 (actual)
- Study completion
- 22 Mar 2026 (actual)
- First posted
- 3 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate a novel VRP.
Detailed description
The primary objective of this study is to determine whether the subjective experience of a novel VRP (DeepDream) will be comparable to a standard dose of psychedelics. This study also looks to compare the subjective experience of DeepDream VRP to other available VR modalities developed to mimic psychedelic subjective experience along with assessing the incidence of VRP adverse effects.
Study design
- Observational model
- Case crossover
- Time perspective
- Other
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Healthy Volunteer | – | Device: Meta Quest 3 |
Who may qualify
- Ages
- 21 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Healthy volunteers
Key inclusion criteria (2 listed)
- Ability to provide informed consent
- No history or current DSM-V diagnosis
Key exclusion criteria (1 listed)
- Unstable medical conditions
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Meta Quest 3Meta Quest 3 is a virtual reality headset device | Device | Healthy Volunteer |
Primary outcome
Assess subjective experience of novel VRP (DeepDream) comparable to a standard dose of psychedelics.
Time frame: Day 0 through Day 30
Subject experience will be assessed using the Altered States of Consciousness Rating Scale.
Assess subjective experience of novel VRP (DeepDream) comparable to a standard dose of psychedelics.
Time frame: Day 0 through Day 30
Subject experience will be assessed using the Mystical Experience Questionnaire.
Assess subjective experience of novel VRP (DeepDream) comparable to a standard dose of psychedelics.
Time frame: Day 0 through Day 30
Subject experience will be assessed using the Ego-Dissolution Inventory.
1 secondary outcome
Assess the incidence of VRP adverse effects, principally virtual reality sickness (VRS) and neck and upper back pain.
Time frame: Day 0 through Day 30
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Aug 2026.
Related trials for Psychedelic Experiences
RecruitingPhase 1
The ENHANCE Study: taVNS and Psilocybin
Healthy, Psychedelic Experiences
Not yet recruitingPhase 1
Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study
Well-Being, Psychological, Psychedelic Experiences
Not yet recruiting
QAIAx (AIhealth4U) - AI Smart Health Cities: Microcity Enclave Program (Quantum AI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360)
Asperger's Disorder, Asperger Disorder
RecruitingEarly Phase 1
Psilocybin Administration With 5-HT1a Blockade
Psychedelic Effects in Healthy Volunteers
RecruitingPhase 2
Subjective Experience Following Psilocybin
Investigating the Importance of the Subjective Psychedelic Experience
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Anahita Bassir Nia, MD principal investigator
Yale University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Psychedelic Experiences and Virtual Reality, run by Yale University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assess subjective experience of novel VRP (DeepDream) comparable to a standard dose of psychedelics. (time frame: Day 0 through Day 30). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Aug 2026.